Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates

Not Applicable

Completed

• Conditions: Enteropathy, Necrotizing Enterocolitis
• Interventions: Other: Collection of stool samples

• Registration Number: NCT02010268
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

This study aims to evaluate a clinico-biological predictive score, associating the faecal calprotectin, for the diagnosis of enterocolitis and enteropathy of the preterm neonates.

Detailed Description

Enteropathy and necrotizing enterocolitis (NEC) are digestive emergencies in premature neonates which represent a major concern for the vital prognosis. It is therefore important to propose a tool for early diagnosis of these intestinal complications in order to avoid extended interruptions of enteral feeding at a period of life where growth (and digestive maturation) is in the foreground. Currently, the diagnosis of digestive impairment is based on classical clinical, biological (CRP, procalcitonin, fecal calprotectin, NFS) and radiological (abdomen without preparation) approaches, which induce on one hand a prolonged interruption of enteral feeding sometimes useless and even harmful for the intestinal maturation and, secondly, the establishment of a parenteral nutrition which is not risk-free. The study propose to dose the fecal calprotectin, a non-invasive marker of digestive inflammation, in order to validate the threshold decision proposed in a pilot study (350 µg/g of feces). Measurement of fecal calprotectin levels will be used as an integrated tool to build a powerful screening score combined to the usual parameters used in routine care for the diagnosis of and enteropathy and necrotizing enterocolitis (NEC) in premature neonates. A cohort of preterm infants born at a gestational age of 33 weeks or less will be included from birth. A stool sample will be collected from the diaper once a week, from birth until discharge from the hospital, and every day during gastrointestinal events (interruption of enteral feeding over 48 hours). The study will evaluate the performance of the rapid assay of fecal calprotectin by quantitative immunochromatography compared to the reference method by enzyme-linked immunosorbent assay (ELISA).

Study Timeline

• Study First Submitted: 2013-08-02
• Study Start: 2013-09-30
• Study First Submitted QC: 2013-12-09
• Study First Posted: 2013-12-12
• Primary Completion: 2015-02-22
• Study Completion: 2015-02-22
• Status Verified: 2017-12
• Last Update Submitted: 2017-12-20
• Last Update Posted: 2017-12-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

• Infants prematurely born at a gestational age of 33 weeks or less (or before the 7th month of pregnancy).
• Patient whose parents or holders of parental authority signed an informed consent.

Exclusion Criteria

• Patient with a malformation.
• Lack of signature of the consent by parents or holders of parental authority.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
preterm neonates	Collection of stool samples	Preterm neonates (birth before 33 weeks of gestation)

Primary Outcome Measures

Name	Time	Method
fecal calprotectin level	From birth to hospital discharge (3 months maximum).	Quantification of fecal calprotectin in stool samples collected every week and the first 3 days during an interruption over 48 hours of enteral feeding

Secondary Outcome Measures

Name	Time	Method
Evaluation of the performance of fecal calprotectin rapid assay.	from birth to hospital discharge (3 months maximum)	The measurement results of fecal calprotectin obtained by the rapid quantitative immunochromatography method, will be compared with those obtained by conventional reference method (ELISA).

Trial Locations

Locations (1)

Necker Hospital; 🇫🇷 Paris, France